Comments to FDA: Evaluating Nicotine Replacement Therapies

CHPA welcomes the opportunity to comment on Nicotine Replacement Therapies (NRT). A number of our member companies hold new drug applications or abbreviated new drug applications for NRT. As such, we have an interest in the subject matter of FDA’s notice.